Assenagon Asset Management
ITCI icon

Assenagon Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Assenagon Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-146,082
Closed -$12.2M – 1368
2024
Q4 		$12.2M Sell
146,082
-86,851
-37% -$7.14M 0.02% 465
2024
Q3 		$17M Sell
232,933
-109,910
-32% -$8.26M 0.03% 385
2024
Q2 		$23.5M Sell
342,843
-306,974
-47% -$21.3M 0.05% 267
2024
Q1 		$45M Sell
649,817
-114,157
-15% -$7.85M 0.11% 154
2023
Q4 		$54.7M Buy
763,974
+275,368
+56% +$15.8M 0.15% 124
2023
Q3 		$25.5M Buy
488,606
+298,303
+157% +$17.4M 0.08% 206
2023
Q2 		$12M Buy
190,303
+57,492
+43% +$3.58M 0.04% 321
2023
Q1 		$7.19M Buy
132,811
+52,583
+66% +$2.54M 0.03% 467
2022
Q4 		$4.25M Buy
80,228
+32,806
+69% +$1.64M 0.02% 569
2022
Q3 		$2.21M Buy
47,422
+8,232
+21% +$430K 0.01% 678
2022
Q2 		$2.24M Sell
39,190
-53,510
-58% -$3.03M 0.01% 796
2022
Q1 		$5.67M Sell
92,700
-35,411
-28% -$1.84M 0.02% 505
2021
Q4 		$6.71M Buy
+128,111
New +$5.38M 0.02% 437
2021
Q2 		– Sell
-208,301
Closed -$7.07M – 1440
2021
Q1 		$7.07M Buy
208,301
+4,313
+2% +$150K 0.03% 423
2020
Q4 		$6.49M Sell
203,988
-271,906
-57% -$7.15M 0.03% 317
2020
Q3 		$12.2M Buy
475,894
+209,143
+78% +$4.77M 0.07% 167
2020
Q2 		$6.85M Buy
266,751
+120,612
+83% +$2.44M 0.04% 256
2020
Q1 		$2.25M Buy
146,139
+127,194
+671% +$2.76M 0.02% 334
2019
Q4 		$650K Buy
+18,945
New +$227K ﹤0.01% 629

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Assenagon Asset Management's ITCI Position: Q1 2025 in Review

Assenagon Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 146,082 shares — an estimated $12.2M sold.

Assenagon Asset Management first reported a position in ITCI in Q4 2019 and held it in 19 quarters. The position peaked at $54.7M in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Assenagon Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 146,082 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $12.2M.
  • Assenagon Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 19 quarters.
  • Assenagon Asset Management's Intra-Cellular Therapies Inc. position peaked at $54.7M in Q4 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Assenagon Asset Management's 13F filing for Q1 2025, filed 15 Apr 2025.